Mounjaro or Tirzepatide is an injectable prescription medication that consists of both glucose dependent insulinotropic peptide (GIP) and Glucagon-like peptide-1 (GLP-1) receptor agonists. GLP-1 and GIP are hormones secreted by stomach and intestines in response to food intake. GLP-1 and GIP decrease hunger, increase satiety, reduce insulin resistance, and promote weight loss. GLP_1 is one of several hundred hormones that plays a central role in weight loss following sleeve gastrectomy.
Endoscopic sleeve gastroplasty or Endosleeve, on the other hand, is a biologically inert procedure. Endosleeve does not alter stomach and intestine hormone secretion following meal intake. Endoscopic sleeve gastroplasty is a mechanically restrictive weight loss procedure like Lap Band. By reducing stomach, endoscopic sleeve gastroplasty forces overweight patients to eat less without altering the neuro-hormonal response to food intake. Consequently, Endosleeve patients reports constant hunger and increased appetite resulting in limited weight loss.
On the other hand, overweight patients on a once weekly injection of Mounjaro, have decreased appetite and hunger levels, and increased satiety and metabolism. Mounjaro, unlike Endosleeve, decreases your food intake without putting you in a starvation mode. This is crucial to achieve long-term and reliable weight loss. If you are looking into a non-surgical weight loss option, GLP_1 agonists are currently a much better option for you than endoscopic sleeve gastroplasty.